For a specified amount of 2.5 mg, divide by the liquid concentration in mg/mL to obtain mL. On a U-100 scale, multiply that volume by 100. At 10 mg/mL this gives 0.25 mL and 25 on the scale. At 5 mg/mL it gives 0.5 mL and 50.
The forward equation and the reverse check
Volume = 2.5 ÷ concentration. U-100 scale marking = 250 ÷ concentration. Reverse check: marking ÷ 100 × concentration = 2.5 mg. The numerator stays fixed while concentration changes the required volume.
Thirteen concentration examples
| Concentration | Volume | U-100 scale marking | Reverse check |
|---|---|---|---|
| 0.5 mg/mL | 5 mL | 500 on U-100 | 5 × 0.5 = 2.5 mg |
| 1 mg/mL | 2.5 mL | 250 on U-100 | 2.5 × 1 = 2.5 mg |
| 2.5 mg/mL | 1 mL | 100 on U-100 | 1 × 2.5 = 2.5 mg |
| 5 mg/mL | 0.5 mL | 50 on U-100 | 0.5 × 5 = 2.5 mg |
| 7.5 mg/mL | 0.333333 mL | 33.333333 on U-100 | 0.333333 × 7.5 = 2.5 mg (rounded display) |
| 10 mg/mL | 0.25 mL | 25 on U-100 | 0.25 × 10 = 2.5 mg |
| 12.5 mg/mL | 0.2 mL | 20 on U-100 | 0.2 × 12.5 = 2.5 mg |
| 15 mg/mL | 0.166667 mL | 16.666667 on U-100 | 0.166667 × 15 = 2.5 mg (rounded display) |
| 20 mg/mL | 0.125 mL | 12.5 on U-100 | 0.125 × 20 = 2.5 mg |
| 25 mg/mL | 0.1 mL | 10 on U-100 | 0.1 × 25 = 2.5 mg |
| 30 mg/mL | 0.083333 mL | 8.333333 on U-100 | 0.083333 × 30 = 2.5 mg (rounded display) |
| 40 mg/mL | 0.0625 mL | 6.25 on U-100 | 0.0625 × 40 = 2.5 mg |
| 50 mg/mL | 0.05 mL | 5 on U-100 | 0.05 × 50 = 2.5 mg |
The rows are hypothetical arithmetic examples, not market-frequency estimates or a list of standard products. Repeating decimal results are displayed to six decimal places; the equation, rather than a rounded printed cell, defines the exact relationship.
How rounding changes the calculated amount
| Concentration | Calculated U-100 marking for 2.5 mg | Alternative marking | Amount at alternative marking | Arithmetic difference |
|---|---|---|---|---|
| 7.5 mg/mL | 33.333333... | 33 | 2.475 mg | -0.025 mg (-1%) |
| 15 mg/mL | 16.666666... | 17 | 2.55 mg | +0.05 mg (+2%) |
These comparisons show the numerical consequence of changing the scale value. They do not identify a universally acceptable rounding tolerance or establish that a device can represent the calculated value. Measurement arithmetic and clinical significance are separate questions.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Scale, capacity and printed increments
At 1 mg/mL, 2.5 mg occupies 2.5 mL, equivalent to 250 on a U-100 scale. That volume does not fit inside a 1 mL barrel. At 5 mg/mL it occupies 0.5 mL, exceeding a 0.3 mL barrel but matching a 0.5 mL capacity. This is a capacity comparison, rather than a reason to silently round or split the calculated volume.
The U-100 calibration does not mean every syringe holds 100 units. Capacity and line increments are device-specific information. A fractional mathematical result is not an additional printed line.
A vial amount needs a corresponding volume
Compare hypothetical totals: 10 mg in 1 mL gives 10 mg/mL, and 10 mg in 2 mL gives 5 mg/mL. The required volume for 2.5 mg changes from 0.25 to 0.5 mL. The total vial amount is the same; the concentration differs.
The words 10 mg on their own do not identify a concentration or establish that the full vial represents one particular amount to administer. The volume denominator remains necessary.
What conversion does not determine
A conversion cannot establish that 2.5 mg is a starting amount for semaglutide, tirzepatide or every GLP-1 medication. It only represents a specified amount in another measurement system. Drug identity, a treatment schedule and a medication amount are different inputs.
The FDA's public measurement report describes differing concentrations and milligram-to-volume calculation errors. The report does not provide a universal error-frequency estimate or an acceptable rounding tolerance.
Frequently asked questions
Is 2.5 mg always 25 units?
It corresponds to 25 on a U-100 scale only at 10 mg/mL. At 20 mg/mL it corresponds to 12.5.
Why does doubling concentration halve the scale reading?
The amount stays fixed. Dividing by twice the concentration gives half the volume, which gives half the reading on the same scale.
Does the medication name supply the conversion?
No. The specified amount, concentration and scale are necessary. The name identifies the product but does not provide a missing volume denominator.
What if the calculated value falls between printed markings?
The calculation and the device's increments are separate information. The equation alone does not establish an acceptable rounding rule.
Related conversion guides
Convert 50 on U-100 back to mg, or compare the amount in a fixed 10-unit volume.
Sources for scale, volume and concentration
- BD syringe portfolio and U-100 scales.
- NIST volume units.
- FDA description of differing concentrations and measurement systems.
Storage and stability after first draw
Unopened vials: Store at 36 to 46°F (2 to 8°C) in the refrigerator. Don't freeze. Storage effects depend on the formulation, so a universal claim that freezing makes every peptide ineffective is not established. If a vial freezes accidentally, discard it.
After first puncture: Most compounding pharmacies label vials "use within 28 days of first puncture" or "discard 28 days after opening." This is a USP <797> standard for multi-dose vials containing preservatives (typically benzyl alcohol or metacresol). Some pharmacies use a 21-day window. Follow the date on your specific vial label.
Room temperature exposure: follow the beyond-use and temperature instructions on your pharmacy label. For comparison, the approved products carry label limits: a Zepbound single-dose pen or vial may be kept at room temperature up to 86°F for a total of 21 days, and a multi-dose vial or KwikPen 30 days (Zepbound label, September 2026). Those approved-product limits do not establish stability for a separately compounded formulation. Correction, September 2026: an earlier version cited a 2023 stability study (Nguyen et al.) and a 24-hour rule; the study could not be found in PubMed, and both have been removed.
Travel: Use an insulated medication bag with a reusable ice pack (not direct ice). Direct contact with ice can freeze the vial. If you're traveling for more than 24 hours, request a travel-size cooler from your pharmacy or buy a medical-grade insulin cooler (brands like FRIO or MedAngel).
Color changes: Clear to faint yellow is normal. Pink, red, or orange tint usually indicates added vitamin B12 (cyanocobalamin), which some pharmacies add. If your vial is colored and the label doesn't mention B12, call the pharmacy. Brown or dark yellow suggests oxidation or contamination. Don't use it.
Cloudiness or particles: Never use a cloudy vial or one with visible floating particles. Peptides can aggregate if temperature-cycled or exposed to light. Aggregated peptide is less effective and potentially more immunogenic (more likely to trigger antibody formation).
When to contact your provider about dose conversion
Contact your prescribing provider within 24 hours if:
1. You drew or injected a significantly different dose than prescribed. A fixed 20% threshold does not establish clinical significance for every formulation and person. Example: You intended 2.5 mg (25 units at 10 mg/mL) but drew 50 units, delivering 5 mg. At 10 mg/mL, 23 rather than 25 on U-100 corresponds to 2.3 rather than 2.5 mg; that arithmetic does not establish clinical significance.
2. You experience severe or persistent side effects after a dose. Severe nausea lasting more than 12 hours, repeated vomiting (more than three episodes), severe abdominal pain, signs of pancreatitis (pain radiating to the back, fever), or signs of gallbladder issues (right upper quadrant pain, jaundice).
3. You're unsure about your vial's concentration and can't reach the pharmacy. Don't guess. If the pharmacy is closed and you can't verify concentration, contact your provider. Without the concentration, the volume-to-amount calculation is incomplete.
4. You switched pharmacies and the new vial's concentration is different. Your provider may need to rewrite dosing instructions in units that match the new concentration.
5. You have signs of an allergic reaction. Hives, swelling of the face or throat, difficulty breathing, rapid heartbeat. This is rare but requires immediate medical attention (call 911, don't wait for a callback).
At 10 mg/mL, 27 rather than 25 on U-100 corresponds to 2.7 rather than 2.5 mg. Whether a deviation matters is your prescriber's judgment, not a fixed arithmetic rule.
FDA status and safety reports as of September 5, 2026
The FDA declared the tirzepatide shortage resolved on December 19, 2024 and the semaglutide shortage on February 21, 2025, and the Fifth Circuit upheld the tirzepatide decision on August 27, 2026; compounded copies are now permitted only for a documented individual clinical need. The FDA's page on unapproved GLP-1 drugs (content current as of September 1, 2026) reports 990 adverse-event reports for compounded semaglutide and more than 730 for compounded tirzepatide as of May 31, 2026, says some may be related to dosing errors, and notes warning letters to firms selling these peptides labeled "for research purposes." Only a vial dispensed by a licensed pharmacy under a prescription carries a concentration you can trust, and current compounded pricing is tracked in the Compounded GLP-1 Price Index.
Footer disclaimers
Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.
Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.
Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.
Trademark Notice. Ozempic, Wegovy, Mounjaro, Zepbound, Rybelsus, Humalog, Novolog, Lantus, and Humulin are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →